# Study of Axitinib in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas

> **NCT02129647** · PHASE2 · COMPLETED · sponsor: **NYU Langone Health** · enrollment: 13 (actual)

## Conditions studied

- Neurofibromatosis Type 2
- Vestibular Schwannomas

## Interventions

- **DRUG:** Axitinib

## Key facts

- **NCT ID:** NCT02129647
- **Lead sponsor:** NYU Langone Health
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-04
- **Primary completion:** 2019-02-05
- **Final completion:** 2019-02-05
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2021-12-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02129647

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02129647, "Study of Axitinib in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02129647. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*